VolitionRX (VNRX) Stock Price, News & Analysis

Company Overview

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

Key Stats

• Today's Range: $0.66 to $0.73
• 50-Day Range: $0.42 to $0.72
• 52-Week Range: $0.40 to $0.90
• Volume: 113,608 shs
• Average Volume: 224,182 shs
• Market Capitalization: $69.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VNRX Stock Analysis - Frequently Asked Questions

How have VNRX shares performed this year?

VolitionRX's stock was trading at $0.58 at the start of the year. Since then, VNRX shares have increased by 15.7% and is now trading at $0.6712.
View the best growth stocks for 2025 here.

How were VolitionRX's earnings last quarter?

VolitionRX Limited (NYSEAMERICAN:VNRX) posted its earnings results on Wednesday, November, 10th. The medical research company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. The medical research company earned $0.03 million during the quarter, compared to the consensus estimate of $0.03 million.

How do I buy shares of VolitionRX?

Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of VolitionRX own?

Based on aggregate information from My MarketBeat watchlists, some other companies that VolitionRX investors own include Chesapeake Energy (CHKAQ), Bausch Health Cos (BHC), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Exelixis (EXEL), T2 Biosystems (TTOO) and Gilead Sciences (GILD).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 6/19/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:VNRX
• Previous Symbol: NYSEMKT:VNRX
• CIK: 93314
• Web: www.volitionrx.com
• Phone: (646) 650-1351
• Fax: 65 32 8172 5651
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.97 million
• Net Margins: -1,835.37%
• Pretax Margin: -1,853.55%
• Return on Equity: N/A
• Return on Assets: -220.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.40
• Quick Ratio: 0.40

Sales & Book Value

• Annual Sales: $1.23 million
• Price / Sales: 56.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.28) per share
• Price / Book: -2.40

Miscellaneous

• Outstanding Shares: 103,020,000
• Free Float: 92,309,000
• Market Cap: $69.15 million
• Optionable: Not Optionable
• Beta: 1.07